Q32 Bio has appointed José Trevejo as its chief medical officer, according to STAT's Pharmalot column. The move adds an executive with prior experience in the same role at another biotech company.
Trevejo joins Q32 Bio from Enveda Therapeutics, where he was chief medical officer and head of clinical pipeline strategy. The report does not detail what he will oversee at Q32 Bio or when he will start.
The news comes from a single source, STAT's weekly roundup of industry appointments, so no independent confirmation or differing accounts are available.